FY2025 EPS Estimates for ChromaDex Increased by Analyst

ChromaDex Co. (NASDAQ:CDXC - Free Report) - Investment analysts at Roth Capital upped their FY2025 EPS estimates for ChromaDex in a research note issued on Wednesday, March 5th. Roth Capital analyst S. Mcgowan now forecasts that the company will post earnings per share of $0.07 for the year, up from their prior forecast of $0.05. The consensus estimate for ChromaDex's current full-year earnings is $0.04 per share. Roth Capital also issued estimates for ChromaDex's Q4 2025 earnings at $0.03 EPS, Q1 2026 earnings at $0.01 EPS, Q2 2026 earnings at $0.02 EPS, Q3 2026 earnings at $0.04 EPS, Q4 2026 earnings at $0.06 EPS and FY2027 earnings at $0.27 EPS.

A number of other analysts have also recently issued reports on the company. LADENBURG THALM/SH SH increased their price objective on ChromaDex from $6.80 to $8.10 and gave the stock a "buy" rating in a report on Wednesday, March 5th. StockNews.com lowered ChromaDex from a "strong-buy" rating to a "buy" rating in a research report on Thursday. Finally, HC Wainwright upped their target price on shares of ChromaDex from $8.00 to $11.00 and gave the stock a "buy" rating in a research report on Monday.

ChromaDex Stock Up 2.3 %

ChromaDex stock traded up $0.18 during mid-day trading on Thursday, reaching $7.88. 1,149,439 shares of the company's stock were exchanged, compared to its average volume of 871,305. The firm has a market capitalization of $612.67 million, a PE ratio of 788.79 and a beta of 2.21. ChromaDex has a one year low of $1.72 and a one year high of $9.18. The business's fifty day simple moving average is $5.77 and its 200 day simple moving average is $5.20.

Remove Ads

Institutional Trading of ChromaDex

Hedge funds and other institutional investors have recently made changes to their positions in the business. Geode Capital Management LLC grew its stake in ChromaDex by 0.5% during the 4th quarter. Geode Capital Management LLC now owns 1,154,778 shares of the company's stock valued at $6,128,000 after acquiring an additional 5,186 shares in the last quarter. D. E. Shaw & Co. Inc. grew its stake in ChromaDex by 1,785.9% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 1,011,290 shares of the company's stock worth $5,365,000 after buying an additional 957,665 shares during the last quarter. Renaissance Technologies LLC lifted its position in ChromaDex by 68.0% during the 4th quarter. Renaissance Technologies LLC now owns 712,788 shares of the company's stock worth $3,781,000 after acquiring an additional 288,588 shares during the period. Arrowstreet Capital Limited Partnership boosted its holdings in ChromaDex by 288.1% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 662,956 shares of the company's stock valued at $3,517,000 after purchasing an additional 492,148 shares in the last quarter. Finally, State Street Corp lifted its holdings in ChromaDex by 11.3% in the third quarter. State Street Corp now owns 618,028 shares of the company's stock valued at $2,256,000 after acquiring an additional 62,692 shares during the period. Institutional investors and hedge funds own 15.41% of the company's stock.

Insider Buying and Selling at ChromaDex

In related news, Director Frank L. Jaksch, Jr. sold 37,161 shares of the firm's stock in a transaction dated Friday, December 13th. The stock was sold at an average price of $6.19, for a total transaction of $230,026.59. Following the sale, the director now owns 244,179 shares of the company's stock, valued at $1,511,468.01. This trade represents a 13.21 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 9.64% of the company's stock.

ChromaDex Company Profile

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.